Clinical Trials Logo
  1. Home
  2. Glomerulonephritis, Membranous
  3. NCT04145440

Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) — M-PLACE  

Glomerulonephritis, Membranous Clinical Trial

Official title:
A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (aMN)

Clinical Trial Summary

This is an open-label, multicentre study to characterize the safety and efficacy of the human anti-CD38 antibody MOR202 in adult subjects with in Anti-PLA2R Antibody Positive Membranous Nephropathy (newly diagnosed/relapsed/refractory)

Clinical Trial Description

After treatment subjects will be observed for up to 1 year. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04145440
Study type Interventional
Source HI-Bio
Contact
Status Completed
Phase Phase 1/Phase 2
Start date October 15, 2019
Completion date August 2, 2022
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01129557 - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Phase 4
Completed NCT00199628 - Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization
Active, not recruiting NCT05656963 - The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
Terminated NCT04154787 - Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy Phase 2
Completed NCT00404794 - A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis Phase 3
Completed NCT03880643 - Rituximab in Refractory Primary Membranous Nephropathy
Not yet recruiting NCT05797051 - Application of Hyperspectral Imaging in the Diagnosis of Glomerular Diseases
Completed NCT00135967 - Mycophenolate Mofetil in Membranous Nephropathy Phase 2/Phase 3
Completed NCT00843856 - Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis Phase 4
Recruiting NCT01282073 - Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy Phase 3
Recruiting NCT05914155 - Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome Phase 3
Completed NCT00135954 - Treatment of Patients With Idiopathic Membranous Nephropathy Phase 3
Completed NCT01610492 - A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy Phase 2
Active, not recruiting NCT03018535 - Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy Phase 3
Completed NCT00404833 - Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental Phase 3
Withdrawn NCT01762852 - Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy Phase 2